Key Points
- CFO Kurt Gustafson sold 6,828 shares on Feb. 17 at an average price of $1.70 for $11,607.60, leaving him with 259,402 shares (a 2.56% reduction in his holding).
- OmniAb shares opened at $1.71, trade in a 12‑month range of $1.22–$4.02, and the company has a market cap of $246.17 million with a negative PE of -2.95.
- Institutional investors own about 72.08% of the stock and have recently increased stakes, while analysts' consensus is a Moderate Buy with an average price target of $6.67 despite a recent Weiss Ratings "sell (e+)".
OmniAb, Inc. (NASDAQ:OABI - Get Free Report) CFO Kurt Gustafson sold 6,828 shares of OmniAb stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $1.70, for a total value of $11,607.60. Following the sale, the chief financial officer directly owned 259,402 shares of the company's stock, valued at $440,983.40. This trade represents a 2.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
OmniAb Trading Up 0.6%
Shares of NASDAQ:OABI opened at $1.71 on Wednesday. OmniAb, Inc. has a twelve month low of $1.22 and a twelve month high of $4.02. The company has a market cap of $246.17 million, a PE ratio of -2.95 and a beta of 0.13. The company's 50 day moving average is $1.89 and its 200 day moving average is $1.76.
Hedge Funds Weigh In On OmniAb
Several institutional investors have recently made changes to their positions in the company. Osaic Holdings Inc. lifted its stake in shares of OmniAb by 214.4% in the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company's stock valued at $25,000 after purchasing an additional 9,716 shares during the period. AQR Capital Management LLC acquired a new stake in OmniAb during the first quarter valued at $25,000. BNP Paribas Financial Markets increased its holdings in OmniAb by 92.5% in the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company's stock valued at $35,000 after buying an additional 10,438 shares in the last quarter. Cerity Partners LLC increased its holdings in OmniAb by 111.5% in the second quarter. Cerity Partners LLC now owns 22,612 shares of the company's stock valued at $39,000 after buying an additional 11,919 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of OmniAb by 96.6% in the fourth quarter. SG Americas Securities LLC now owns 23,141 shares of the company's stock worth $43,000 after acquiring an additional 11,369 shares during the period. 72.08% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of OmniAb in a report on Monday, December 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $6.67.
View Our Latest Research Report on OABI
OmniAb Company Profile
(
Get Free Report)
OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.
Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
